1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>France

Genfit Positions To Battle Intercept On Both NASH And PBC Fronts

While beginning to enroll the Phase III trial of elafibranor in NASH, Genfit also plans to study the drug in PBC, an indication in which top competitor Intercept could receive FDA approval this quarter.

Genfit SA used its recent R&D day to argue that its elafibranor is best suited to become the first-line treatment for non-alcoholic steatohepatitis (NASH) due to better tolerability than Intercept Pharmaceuticals Inc.'s obeticholic acid (OCA), and because of its work with biomarkers to determine which patients need to be treated.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from France

More from Europe

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

UK Mandates Unmodified Standardized Contracts To Speed Clinical Trial Set-Up

 
• By Vibha Sharma

The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.

New EU Filings

 
• By Neena Brizmohun

Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.